Candidemia and infections by Clostridium difficile and carbapenemaseproducing Enterobacteriaceae: New enteropathogenetic opportunistic syndromes?;Candidemia e infezioni da Clostridium difficile ed enterobatteri carbapenemasi-produttori: Nuove sindromi enteropatogenetiche opportunistiche?

Infezioni in Medicina

Volumn 23, Issue 2, 2015, Pages 105-116

  De Rosa, Francesco Giuseppe ^a   Corcione, Silvia ^a   Raviolo, Stefania ^a   Montrucchio, Chiara ^a   Aldieri, Chiara ^a   Pagani, Nicole ^a   Di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

C; Candidemia; Carbapenemases; Difficile infection; Enteropathogenesis; KPC Kp; Opportunistic infection

Indexed keywords

CARBAPENEM; CEPHALOSPORIN; CLINDAMYCIN; ECHINOCANDIN; FIDAXOMICIN; PENICILLIN DERIVATIVE; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE;

ABDOMINAL SURGERY; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; CANDIDA; CANDIDEMIA; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CHEMOTHERAPY; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; FEVER; HUMAN; INTESTINE FLORA; KLEBSIELLA PNEUMONIAE INFECTION; LENGTH OF STAY; LIVER CIRRHOSIS; MORTALITY; MULTICENTER STUDY (TOPIC); NEUROLOGIC DISEASE; OPPORTUNISTIC INFECTION; PEPTOCLOSTRIDIUM DIFFICILE; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEPSIS; SYSTEMATIC REVIEW (TOPIC); BIOSYNTHESIS; CLOSTRIDIUM INFECTIONS; COMPLICATION; CROSS INFECTION; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; GENETICS; INCIDENCE; ISOLATION AND PURIFICATION; ITALY; OPPORTUNISTIC INFECTIONS; SECRETION (PROCESS); SYNDROME;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CANDIDEMIA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; ENTEROBACTERIACEAE INFECTIONS; HUMANS; INCIDENCE; ITALY; OPPORTUNISTIC INFECTIONS; SYNDROME;

EID: 84936952182     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. De Rosa F.G., Corcione S., Filippini C., et al. The effect on mortality of fluconazole or echinocandins treatment in internal medicine wards. PLoS One. 10, e0125149, 2015.
2. Guastalegname M., Russo A., Falcone M., Giuliano S., Venditti M. Candidemia subsequent to severe infection due to Clostridium difficile: is there a link? Clin. Infect. Dis. 57, 772-774, 2013.
3. Giacobbe D.R., Del Bono V., Marchese A., Viscoli C. Early carbapenem-resistant Klebsiella pneumoniae bacteraemia: should we expand the screening? Clin. Microbiol. Infect. 20, O1157-8, 2014.
4. Giuliano S., Guastalegname M., Jenco M., Morelli A., Falcone M., Venditti M. Severe community onset healthcare-associated Clostridium difficile infection complicated by carbapenemase producing Klebsiella pneumoniae bloodstream infection. BMC Infect. Dis. 14, 475, 2014.
5. Bassetti M., Molinari M.P., Mussap M., Viscoli C., Righi E. Candidaemia in internal medicine departments: the burden of a rising problem. Clin. Microbiol. Infect. 19, E281-4, 2013.
6. Tyler A.D., Smith M.I., Siverberg M.S. Analyzing the human microbiome: a "how to" guide for physicians. Am. J. Gastroenterol. 109, 983-993, 2014.
7. Turnbaugh P.J., Ley R.E., Hamady M., Fraser-Liggett C.M., Knight R., Gordon J.I. The Human Microbiome project. Nature. 449, 804-810, 2007.
8. Cho I., Blaser M.J. The human microbiome: at the interface of health and disease. Nature. 13, 260-270, 2012.
9. Erlich S.D. Metagenomics of the human body. Springer. 307-316, 2011.
10. De Rosa F.G., Corcione S., Pagani N., Di Perri G. From ESKAPE to ESCAPE, from KPC to CCC. Clin. Infect. Dis. 60, 1289-1290, 2015.
11. Scudeller L., Viscoli C., Menichetti F., et al. An Italian Consensus for invasive candidiasis management (ITALIC). Infection. 42, 263-279, 2014.
12. Miranda L.N., van der Heijden I.M., Costa S.F., et al. Candida colonisation as a source for candidaemia. J. Hosp. Infect. 72, 9-16, 2009.
13. Nucci M., Anaissie E. Revisiting the source of can didemia: skin or gut? Clin. Infect. Dis. 33, 1959-1967, 2001.
14. Evans C.T., Safdar N. Current Trends in the Epidemiology and Outcomes of Clostridium difficile Infection. Clin. Infect. Dis. 60 (Suppl. 2), S66-71, 2015.
15. Loo V.G., Bourgault A.M., Poirier L., Lamothe F., et al. Host and pathogen factors for Clostridium difficile infection and colonization. N. Engl. J. Med. 365, 1693- 1703, 2011.
16. Cheng A.C., Ferguson J.K., Richards M.J., et al. Australian Society for Infectious Diseases. Australasian Society for Infectious Diseases guidelines for the diagnosis and treatment of Clostridium difficile infection. Med. J. Aust. 194, 353-358, 2011.
17. McFarland L.V., Mulligan M.E., Kwok R.Y., Stamm W.E. Nosocomial acquisition of Clostridium difficile infection. N. Engl. J. Med. 320, 204-210, 1989.
18. Shaughnessy M.K., Micielli R.L., Depestel D.D., et al. Evaluation of hospital room assignment and acquisition of Clostridium difficile infection. Infect. Control Hosp. Epidemiol. 32, 201-206, 2011.
19. Tumbarello M., Viale P., Viscoli C., et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin. Infect. Dis. 55, 943-950, 2012.
20. Corcione S., Rocchetti A., Argentero P.A. et al. A one-year survey of carbapenemase-producing Klebsiella pneumoniae in Italy: beyond the ICU. Clin. Microbiol. Infect. 21, e11-3, 2015.
21. Giani T., Pini B., Arena F., et al. Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey, 15 May to 30 June 2011. Euro. Surveill. 30, 18(22), 1-9, 2013.
22. Kaukonen K.M., Bailey M., Pilcher D., Cooper D.J., Bellomo R. Systemic inflammatory response syndrome criteria in defining severe sepsis. N. Engl. J. Med. 372, 1629-1638, 2015.
23. Cleveland A.A., Farley M.M., Harrison L.H., et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin. Infect. Dis. 55, 1352-1361, 2012.
24. Eggimann P., Que Y.A., Revelly J.P., Pagani J.L. Preventing invasive candida infections. Where could we do better? J. Hosp. Infect. 89, 302-308, 2015.
25. De Rosa F.G., Trecarichi E.M., Montrucchio C., et al. Mortality in patients with early- or late-onset candidaemia. J. Antimicrob. Chemother. 68, 927-935, 2013.
26. Chakrabarti A., Sood P., Rudramurthy S.M., et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med. 41, 285-295, 2015.
27. Playford E.G., Marriott D., Nguyen Q., et al. Candidemia in non neutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit. Care Med. 36, 2034-2039, 2008.
28. Leroy O., Gangneux J.P., Montravers P., et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France. Crit. Care Med. 37, 1612-1618, 2009.
29. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: http://www.cdc.gov/drugresistance/threat-report- 2013/. Last accessed September 15, 2014.
30. Tartof S.Y., Yu K.C., Wei R., Tseng H.F., Jacobsen S.J., Rieg G.K. Incidence of polymerase chain reactiondiagnosed C. difficile in a large high-risk cohort, 2011- 2012. Mayo Clin. Proc. 89, 1229-1238, 2014.
31. Gupta A., Khanna S.. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect. Drug. Resist. 7, 63-72, 2014.
32. De Rosa F.G., Cavallerio P., Corcione S., et al. Molecular characterization of toxigenic Clostridium difficile in a northern Italian hospital. Curr. Microbiol. 70, 154- 155, 2015.
33. Chen L.F., Anderson D.J., Paterson D.L. Overview of the epidemiology and the threat of Klebsiella pneumoniae carbapenemases (KPC) resistance. Infect. Drug. Resist. 5, 133-141, 2012.
34. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). ECDC, Stockholm, Sweden 2013.
35. Qureshi Z.A., Paterson D.L., Potoski B.A., et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob. Ag. Chemother. 56, 2108-2113, 2012.
36. Giani T., Pini B., Arena F., et al. Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey, 15 May to 30 June 2011. Euro. Surveill. 18, pii:20489, 2013.
37. Eggimann P., Bille J., Marchetti O., et al. Diagnosis of invasive candidiasis in the ICU. Ann. Intens. Care. 1, 37-46, 2011.
38. Maubon D., Garnaud C., Calandra T., Sanglard D., Cornet M. Resistance of Candida spp. to antifungal drugs in the ICU: where are we now? Intens. Care Med. 40, 1241-1255, 2014.
39. Eggimann P., Pittet D. Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later. Intens. Care Med. 40, 1429-1448, 2014.
40. McFarland L.V. Renewed interest in a difficult disease: Clostridium difficile infections-epidemiology and current treatment strategies. Curr. Opin. Gastroenterol. 25, 24-35, 2009.
41. Huang H., Wu S., Chen R., Xu S., et al. Risk fac tors of Clostridium difficile infections among patients in a university hospital in Shanghai, China. Anaerobe 30, 65-69, 2014.
42. Walker AS, Eyre DW, Wyllie DH, et al. Characterisation of Clostridium difficile hospital ward-based transmission using extensive epidemiological data and molecular typing. PLoS Med. e1001172, 2012.
43. Kazakova S.V., Ware K., Baughman B., et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch. Intern. Med. 166, 2518-2524, 2006.
44. Muto C.A., Pokrywka M., Shutt K., et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. 26, 273-280, 2005.
45. Loo V.G., Poirier L., Miller M.A, et al. A predominantly clonal multi-institutional outbreak of C. difficileassociated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353, 2442-2449, 2005.
46. Pepin J., Saheb N., Coulombe M.A., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41, 1254-1260, 2005.
47. Dubberke E.R., Reske K.A., Yan Y., Olsen M.A., Mc- Donald L.C., Fraser V.J. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin. Infect. Dis. 45, 1543-1549, 2007.
48. Owens R.C., Donskey C.J., Gaynes R.P., Loo V.G., Muto C.A. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin. Infect. Dis. 46, 19-31, 2008.
49. McCusker M.E., Harris A.D., Perencevich E., Roghmann M. Fluoroquinolone use and Clostridium difficileassociated diarrhea. Emerg. Infect. Dis. 9, 730-733, 2003.
50. Gerding D.N., Olson M.M., Peterson L.R., et al. Clostridium difficile-associated diarrhea and colitis in adults. Arch. Intern. Med. 146, 95-100, 1986.
51. Brown E., Talbot G.H., Axelrod P., Provencher M., Hoegg C. Risk factors for Clostridium difficile toxin-associated diarrhea. Infect. Control Hosp. Epidemiol.11, 283- 290, 1990.
52. Kwok C.S., Arthur A.K., Anibueze C.I., Singh S., Cavallazzi R., Loke Y.K. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am. J. Gastroenterol. 107, 1011-1019, 2012.
53. Shah S, Lewis A, Leopold D, Dunstan F, Woodhouse K. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM. 93, 175-181, 2000.
54. Furuya-Kanamori L., Stone J.C., Clark J., et al. Comorbidities, exposure to medications, and the risk of community-acquired Clostridium difficile infection: a systematic review and meta-analysis. Infect. Cont. Hosp. Epidemiol. 36, 132-141, 2015.
55. McFarland L.V., Elmer G.W., Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am. J. Gastroenterol. 97, 1769-1775, 2002.
56. Eyre D.W., Walker A.S., Wyllie D., et al. Predictors of first recurrence of Clostridium difficile infection: Implications for initial management. Clin. Infect. Dis. 55, S77-S87, 2012.
57. Hu M.Y., Katchar K., Kyne L., et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology. 136, 1206-14, 2009.
58. Kelly J.P. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin. Microbiol. Infect. 18, 21-27, 2012.
59. Fekety R., McFarland L.V., Surawicz C.M., Greenberg R.N., Elmer G.W., Mulligan M.E. Recurrent Clostridium difficile diarrhea: Characteristics of and the risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin. Infect. Dis. 24, 324-333, 1997.
60. Samie A.A., Traub M., Bachmann K., Kopischke K., Theilmann L. Risk factors for recurrence of Clostridium difficile-associated diarrhea. Hepatogastroenterology 60, 1351-1354, 2013.
61. Tumbarello M., Trecarichi E.M., Tumietto F., et al. Predictive models for identification of hospitalized patient sharboring KPC-producing Klebsiella pneumoniae. Antimicrob. Ag. Chemother. 58, 3514-3520, 2014.
62. Giannella M., Trecarichi E.M., De Rosa F.G., et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicenter study. Clin. Microbiol. Infect. 20, 1357-1362, 2014.
63. Montravers P., Dupont H., Eggimann P. Intraabdominal candidiasis: the guidelines-forgotten noncandidemic invasive candidiasis. Intens. Care Med. 39, 2226-2230, 2013.
64. Tacconelli E., Cataldo M.A., Dancer S.J., et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrugresistant Gram-negative bacteria in hospitalized patients. Clin. Microbiol. Infect. 20 (Suppl. 1), 1-55, 2014.
65. Papadimitriou-Olivgeris M., Spiliopoulou A., Fligou F., et al. Association of KPC-producing Klebsiella pneumoniae colonization or infection with Candida isolation and selection of non-albicans species. Diagn. Microbiol. Infect. Dis. 80, 227-233, 2014.
66. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control. Hosp. Epidemiol. 31, 431-455, 2010.
67. Corcione S., Cardellino C.S., Calcagno A., et al. Healthcare-associated Klebsiella pneumoniae car bapenemase producing K. pneumoniae bloodstream infection: the time has come. Clin. Infect. Dis. 59, 321-322, 2014.
68. Bassetti M., De Waele J.J., Eggimann P., et al. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med. 41, 776-795, 2015.
69. Ashiru-Oredope D., Sharland M., Charani E., Mc- Nulty C., Cooke J. ARHAI Antimicrobial Stewardship Group. Improving the quality of antibiotic prescribing in the NHS by developing a new Antimicrobial Stewardship Programme: Start Smart--Then Focus. J. Antimicrob. Chemother. 67 (Suppl. 1), i51-i63, 2012.
70. Nerandzic M.M., Mullane K., Miller M.A., Babakhani F., Donskey C.J. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin. Infect. Dis. 55, S121-S126, 2012.
71. Menian F.A., Bryant A. Does Candida species overgrowth protect against Clostridium difficile infection? Clin. Infect. Dis. 56, 464-465, 2013.
72. Raponi G., Visconti V., Brunetti G., Ghezzi M.C. Clostridium difficile infection and Candida colonization of the gut: is there a correlation? Clin. Infect. Dis. 59, 1648-1649, 2014.
73. Russo A., Falcone M., Fantoni M., et al. Risk factors and clinical outcomes of candidaemia in patients treated for Clostridium difficile infection. Clin. Microbiol. Infect. Ahead of print, doi: 10.1016/j.cmi.2014.12.024. 2015.